Quest for the right Drug
סטמיציס STAMICIS 1 MG KIT FOR RADIOPHARMACEUTICAL PREPATION (TETRAKIS COPPER (I) TETRAFLUOROBORATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
אבקה מיובשת בהקפאה להכנת תמיסה להזרקה : LYOPHILIZED POWDER FOR SOLUTION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
4.2 Posology and method of administration Posology Adults and elderly population Posology may vary depending on gamma camera characteristics and reconstruction modalities. The injection of activities greater than local DRLs (Diagnostic Reference Levels) should be justified. The recommended activity range for intravenous administration to an adult patient of average weight (70 kg) is for: Diagnosis of reduced coronary perfusion and myocardial infarction 400-900 MBq. The recommended activity range for diagnosis of ischaemic heart disease according to the European procedural guideline is: – Two-day protocol: 600–900 MBq/study – One-day protocol: 400–500 MBq for the first injection, three times more for the second injection. Not more than a total of 2000 MBq should be administered for a one-day protocol and 1800 MBq for a two-day-protocol. For a one-day protocol, the two injections (stress and rest) should be done at least two hours apart but may be performed in either order. After the stress injection, exercise should be encouraged for an additional one minute (if possible). For diagnosis of myocardial infarction one injection at rest is usually sufficient. For diagnosis of ischaemic heart disease two injections (stress and rest) are required in order to differentiate transiently from persistently reduced myocardial uptake. Assessment of global ventricular function: 600-800 MBq injected as a bolus. Scintimammography: 700-1000 MBq injected as a bolus usually in the arm opposite to the lesion. Localisation of hyperfunctioning parathyroid tissue: 200-700 MBq injected as a bolus. The typical activity is between 500-700 MBq. Renal impairment Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients. Hepatic impairment In general, activity selection for patients with a decreased hepatic function should be cautious, usually starting at the low end of the dosing range. Paediatric population The use in children and adolescents has to be considered carefully, based upon clinical needs and assessing the risk/benefit ratio in this patient group. The activities to be administeredto children and adolescents may be calculated according to the recommendations of the European Association of Nuclear Medicine (EANM) paediatric dosage card; the activity administered to children and to adolescents may be calculated by multiplying a baseline activity (for calculation purposes) by the weight-dependent multiples given in the table below. A[MBq]Administered = Baseline Activity X Multiple: The baseline activity is 63 MBq as a cancer seeking agent. For cardiac imaging, the minimum and maximum baseline activities are 42 and 63 MBq, respectively, for the two-day protocol cardiac scan both at rest and stress. For the one-day cardiac imaging protocol, the baseline activity is 28 MBq at rest and 84 MBq at stress. The minimum activity for any imaging study is 80 MBq. Weight Multiple Weight Multiple Weight Multiple [kg] [kg [kg] 3 1 22 5.29 42 9.14 4 1.14 24 5.71 44 9.57 6 1.71 26 6.14 46 10.00 8 2.14 28 6.43 48 10.29 10 2.71 30 6.86 50 10.71 12 3.14 32 7.29 52-54 11.29 14 3.57 34 7.72 56-58 12.00 16 4.00 36 8.00 60-62 12.71 18 4.43 38 8.43 64-66 13.43 20 4.86 40 8.86 68 14.00 Method of administration For intravenous use. Because of potential tissue damage, extravasal injection of this radioactive product has to be strictly avoided. For multidose use. Precautions to be taken before handling or administration of the medicinal product This medicinal product should be reconstituted before administration to the patient. For instructions on reconstitution and control of the radiochemical purity of the medicinal product before administration, see section 12. For patient preparation, see section 4.4. Image acquisition Cardiac imaging Imaging should begin approximately after 30-60 min after injection to allow for hepatobiliary clearance. Longer delay can be required for resting images and for stress with vasodilatators alone because of the risk of higher subdiaphragmatic technetium (99mTc) activity. There is no evidence for significant changes in myocardial tracer concentration or redistribution, therefore imaging for up to 6 hours post injection is possible. Test may be done in a one day or two days protocol. Preferably tomographic imaging (SPECT) with or without ECG gating should be performed. Scintimammography Breast imaging is optimally initiated 5 to 10 minutes post injection with the patient in the prone position with breast freely pendant. The product is administered in an arm vein contralateral to the breast with the suspected abnormality. If the disease is bilateral, the injection is ideally administered in a dorsal vein of the foot. Conventional gamma camera The patient should then be repositioned so that the contralateral breast is pendant and a lateral image of it should be obtained. An anterior supine image may then be obtained with the patient’s arms behind her head. Detector dedicated to breast imaging In case a detector dedicated to breast imaging is used, a relevant machine-specific protocol must be followed to obtain the best possible imaging performance. Parathyroid imaging Parathyroid image acquisition depends on the protocol chosen. The most used studies are either the subtraction and/or the dual-phase techniques, which can be performed together. For the subtraction technique either sodium iodide (123I) or sodium pertechnetate (99mTc) can be used for imaging for the thyroid gland since these radiopharmaceuticals are trapped by functioning thyroid tissue. This image is subtracted from the technetium (99mTc) sestamibi image, and pathological hyperfunctioning parathyroid tissue remains visible after subtraction. When sodium iodide ( 123I) is used, 10 to 20 MBq are orally administered. Four hours after the administration, neck and thorax images may be obtained. After sodium iodide (123I) image acquisition, 200 to 700 MBq of technetium (99mTc) sestamibi are injected and images are acquired 10 minutes post injection in double acquisition” with 2 peaks of gamma energy (140 keV for technetium (99mTc) and 159 keV for iodine (123I)). When sodium pertechnetate (99mTc) is used, 40-150 MBq are injected and neck and thorax images are acquired 30 minutes later. Then 200 to 700 MBq of technetium (99mTc) sestamibi are injected and a second acquisition of images is acquired 10 minutes later. When the dual phase technique is used, 400 to 700 MBq of technetium (99mTc) sestamibi are injected and the first neck and mediastinum image is obtained 10 minutes later. After a wash-out period of 1 to 2 hours, neck and mediastinum imaging is again performed. The planar images may be complemented by early and delayed SPECT or SPECT/CT.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
ATC
מידע נוסף